去纤维钠治疗肝小静脉闭塞病患者的效果好吗？

(Defitelio) is a mixture derived from the porcine intestinal mongolic membrane. Its mechanism of action is not yet fully understood, but it has fibrinolytic effects and protects endothelial cells. It increases fibrin lysis and modulates platelet activity to reduce procoagulant activity. It has not been reported to increase the risk of bleeding. Using fiber sodium to treat patients with hepatic veno-occlusive disease can not only reduce the patient's symptoms, but also improve the patient's quality of life.

Clinical trials of defibrinated sodium to prevent stem cell transplant patients, a high-risk group for VOD, have also been carried out on a large scale and have made promising progress. While heparin is used to prevent diseases such as VOD, it greatly increases the risk of bleeding. However, when DF is used alone or in combination with heparin, the incidence of side effects is very low, and it has achieved a good effect in preventing VOD.

In a phase III multi-center randomized clinical trial completed in Europe, a total of 356 stem cell transplant patients were recruited. When comparing the incidence of VOD 30 days after transplantation, 22 of 180 patients in the defibrinated sodium group developed VOD, accounting for 12%; 35 of 176 patients in the control group developed VOD, accounting for 20%.

Clinical data accumulated so far show that defibrotide sodium (ie defibrotide) treatment is well tolerated by patients. In a foreign clinical trial, the incidence rate of grade 3-4 side effects related to defibrinated sodium was 7%, mainly hypotension, pulmonary and gastrointestinal bleeding, and abdominal cramps. Only 4% of patients stopped treatment due to side effects. There were no reports of death of patients directly caused by the use of defibrinated sodium.

In a phase III clinical trial, the risk of bleeding in the Defitelio treatment group was similar to that in the historical control group, with 18% of patients discontinuing treatment due to DF-related toxicity. (Defitelio) has significant clinical efficacy and good tolerability in the prevention and treatment of VOD. Defiber sodium has been successfully launched for the indication of VOD.

Recommended hot articles: /newsDetail/78611.html